• Home
  • Study Details
By physician referral or invitation only

ACNS2321 (CNS Germinoma, Reduced Radiotherapy)

The purpose of this study is to determine if treating germinomas with chemotherapy followed by a lower dose of radiotherapy (RT) can be as effective as the current standard of care. Specifically, our primary aim is to determine whether 12 Gy whole ventricular irradiation (WVI) and 12 Gy tumor boost would maintain similar efficacy compared to ACNS1123 stratum 2 as measured by event-free survival (EFS) in eligible patients with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGß) = 100 IU/L and normal AFP, and meet complete response (CR) or continued complete response (CCR) criteria following chemotherapy/second-look surgery (Stratum 1). We are attempting to build upon the excellent results of ACNS1123 stratum 2 by reducing the RT dose even further for patients in a CR after chemotherapy.

Age & Gender

  • 3 years ~ 29.9 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

David Kram
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pediatric Cancers)

IRB Number

25-0533

ClinicalTrials.gov

NCT06368817

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research